Company news

Alkermes plc news in 2019

Alkermes plc's news releases, calls and decks from 2019, newest first.

View company

Alkermes Completes Acquisition of Rodin Therapeutics

November 24, 2019

Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder

November 18, 2019

Alkermes to Acquire Rodin Therapeutics

November 17, 2019

Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY(TM)

November 11, 2019

Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

November 7, 2019

Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

November 3, 2019

Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring

October 22, 2019

Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230

October 20, 2019

Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results

October 15, 2019

Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute

July 28, 2019

Alkermes Plc Reports Second Quarter 2019 Financial Results

July 24, 2019

Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results

July 17, 2019

Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder

July 14, 2019

Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

June 11, 2019

Alkermes Plc Reports First Quarter 2019 Financial Results

April 24, 2019

Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and Marketing

April 23, 2019

Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results

April 17, 2019

Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

April 8, 2019

Alkermes Announces Departure of Jim Robinson

April 7, 2019

Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia

April 2, 2019

Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society

March 31, 2019

Decks in 2019